Skip to main content
David Miklos, MD, Oncology, Stanford, CA, Stanford Health Care

DavidBernardMiklosMDPhD

Oncology • Stanford, CA

Hematologic Oncology

Associate Professor of Medicine & Associate Chief - Blood & Marrow Transplantation, Clinical Director - Cancer Cell Therapy Program, Stanford University Medical Center

Join to view full profile

Dr. Miklos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Miklos' full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
  • Yale School of Medicine
    Yale School of MedicineClass of 1995

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - 2026
  • MA State Medical License
    MA State Medical License 2001 - 2006
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Ibrutinib for Chronic Pulmonary Graft-Versus-Host-Disease after Progression on Prior Therapy
    David B. Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
    David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel
    David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

  • Blood Test Predicts Chances of Lymphoma Relapse After Therapy
    Blood Test Predicts Chances of Lymphoma Relapse After TherapyAugust 6th, 2021
  • Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood Cancers
    Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
  • KTE-X19 Poised to Have Promising Future in MCL Paradigm
    KTE-X19 Poised to Have Promising Future in MCL ParadigmFebruary 22nd, 2020
  • Join now to see all

Grant Support

  • Biology And Treatment Of Cutaneous SclerosisNational Cancer Institute2011
  • Allogeneic B Cell ResponsesNational Cancer Institute2007–2011
  • Biology And Treatment Of Cutaneous SclerosisNational Institute Of Allergy And Infectious Diseases2009–2010
  • Microarray Analysis Of H-Y Antibodies In Human TransplantationNational Heart, Lung, And Blood Institute2007–2008
  • Identification Of Minor Histocompatibility AntigensNational Heart, Lung, And Blood Institute2005–2006
  • Identification Of Minor Histocompatibility AntigensNational Heart, Lung, And Blood Institute2002–2004

Hospital Affiliations

Dr. David Miklos, Dr. David Miklos, MD, Dr. D Miklos, Dr. David Bernard Miklos